Fuji Pharma Co., Ltd. (TYO:4554)
Japan · Delayed Price · Currency is JPY | Market Cap | 32.37B |
| Revenue (ttm) | 48.85B |
| Net Income (ttm) | 3.18B |
| Shares Out | 24.43M |
| EPS (ttm) | 130.48 |
| PE Ratio | 10.15 |
| Forward PE | 8.98 |
| Dividend | 45.50 (3.41%) |
| Ex-Dividend Date | Sep 29, 2025 |
| Volume | 58,300 |
| Average Volume | 57,395 |
| Open | 1,334.00 |
| Previous Close | 1,335.00 |
| Day's Range | 1,321.00 - 1,334.00 |
| 52-Week Range | 1,089.00 - 1,643.00 |
| Beta | 0.27 |
| RSI | 50.55 |
| Earnings Date | Aug 7, 2025 |
About Fuji Pharma
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, as well as information regarding pharmaceuticals and health; and contract manufacturing services. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan. [Read more]
Full Company ProfileFinancial Performance
In 2024, Fuji Pharma's revenue was 46.14 billion, an increase of 12.84% compared to the previous year's 40.89 billion. Earnings were 6.15 billion, an increase of 78.92%.
Financial StatementsNews
Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility
REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO , ALVO SDB, the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients w...
Olic anticipates buoyant demand for contraceptives
The contraceptive market is expected to grow in Southeast Asia, driven by informed individuals' increasing awareness of health issues and a trend of having no children, says Olic (Thailand) Ltd, a sub...